89bio, Inc. (ETNB) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
89bio Inc. (ETNB) PT Lowered to $12 at RBC Capital
August 6, 2024 6:41 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on 89bio Inc. (NASDAQ: ETNB) to $12.00 (from $13.00) while maintaining a Sector Perform rating.
The analyst comments "Both ph.III studies in MASH have been initiated and are enrolling. While we like pegoza's likely role... More
